Abstract
ADAM28 is a member of the ADAM (a disintegrin and metalloproteinase) gene family and consists of two isoforms, prototype membrane-type form and short secreted form. The metalloproteinase domain of ADAM28 has the zincbinding consensus sequence, andADAM28 exhibits catalytic activity to a few substrates such as insulin-like growth factor binding protein-3. The disintegrin domain interacts with integrins α4β1, α4β7 and α9β1. In human non-small cell lung carcinomas and breast carcinomas, ADAM28 is overexpressed predominantly by carcinoma cells, and the expression correlates with carcinoma cell proliferation and lymph node metastasis. In this review we present our data on the activation of proADAM28, the tissue localization in human cancers and the interaction molecules, and discuss the regulation of ADAM28 activity and gene expression, the functions of ADAM28 in human cancers and the possibility of ADAM28 as a target for cancers.
Keywords: ADAM28, proliferation, invasion, metastasis, MMP, IGFBP-3, PSGL-1, integrin
Current Pharmaceutical Design
Title: ADAM28 as a Target for Human Cancers
Volume: 15 Issue: 20
Author(s): Satsuki Mochizuki and Yasunori Okada
Affiliation:
Keywords: ADAM28, proliferation, invasion, metastasis, MMP, IGFBP-3, PSGL-1, integrin
Abstract: ADAM28 is a member of the ADAM (a disintegrin and metalloproteinase) gene family and consists of two isoforms, prototype membrane-type form and short secreted form. The metalloproteinase domain of ADAM28 has the zincbinding consensus sequence, andADAM28 exhibits catalytic activity to a few substrates such as insulin-like growth factor binding protein-3. The disintegrin domain interacts with integrins α4β1, α4β7 and α9β1. In human non-small cell lung carcinomas and breast carcinomas, ADAM28 is overexpressed predominantly by carcinoma cells, and the expression correlates with carcinoma cell proliferation and lymph node metastasis. In this review we present our data on the activation of proADAM28, the tissue localization in human cancers and the interaction molecules, and discuss the regulation of ADAM28 activity and gene expression, the functions of ADAM28 in human cancers and the possibility of ADAM28 as a target for cancers.
Export Options
About this article
Cite this article as:
Mochizuki Satsuki and Okada Yasunori, ADAM28 as a Target for Human Cancers, Current Pharmaceutical Design 2009; 15 (20) . https://dx.doi.org/10.2174/138161209788682424
DOI https://dx.doi.org/10.2174/138161209788682424 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Wnt Signaling and Potential Applications in Bone Diseases
Current Drug Targets Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry Clinical-Grade Oncolytic Adenovirus Purification Using Polysorbate 20 as an Alternative for Cell Lysis
Current Gene Therapy Osteoblast Differentiation and Control by Vitamin D and Vitamin D Metabolites
Current Pharmaceutical Design The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry p38 MAPK: A Potential Target of Chronic Pain
Current Medicinal Chemistry The Stem Cell Niche as a Pharmaceutical Target for Prevention of Skeletal Metastases
Anti-Cancer Agents in Medicinal Chemistry Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Integrins Modulate Cellular Fibrogenesis at Multiple Levels: Regulation of TGF-β Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology The Early Bird Catches the Worm – Can Evolution Teach us Lessons in Fighting HIV?
Current HIV Research Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design MicroRNAs Implications in the Onset, Diagnosis, and Prognosis of Osteosarcoma
Current Molecular Medicine Improving the Targeting of Tubulin-Binding Agents: Lessons from Drug Resistance Studies
Current Pharmaceutical Design Dimethylaminoparthenolide, A Water Soluble Parthenolide, Suppresses Lung Tumorigenesis Through Down-Regulating the STAT3 Signaling Pathway
Current Cancer Drug Targets Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine Recent Advances in Copper Radiopharmaceuticals
Current Radiopharmaceuticals Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Time Dependent Distribution of MicroRNA 144 after Intravenous Delivery
MicroRNA Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry